Microcyto微元合成 logo — 微元合成(Microcyto)是一家以合成生物技术为基础的生物制造公...

Microcyto微元合成

微元合成(Microcyto)是一家以合成生物技术为基础的生物制造公司,至今 已完成多家明星投资机构参与的大额融资,已与多家国企和外企建立了广泛的交流与合作。公司业务聚焦于活性原料药、高附加值天然产物和大宗平台化合物等品类。

Founded 2021 China China 7 employees Seed Total: $100.00M Biotechnology, Food and Beverage +1

General Information

Company Name Microcyto微元合成
Founded Year 2021
Location China China +1
Employees 7
Industries Biotechnology, Food and Beverage, Manufacturing
Funding Stage Seed
Social

Get notified when Microcyto微元合成 moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Microcyto微元合成

Microcyto微元合成, founded in 2021 and headquartered in China, is a biotech powerhouse focusing on synthetic biology for biomanufacturing. The company's niche lies in developing active pharmaceutical ingredients, high-value natural products, and bulk chemicals. It is effectively tapping into a range of sectors, including pharmaceuticals, cosmetics, agriculture, food, feed, and materials.

The company's core team comprises experts from top Chinese research institutions such as the Chinese Academy of Sciences, Tsinghua University, and Sichuan University. Microcyto's innovative approach has garnered substantial attention, evidenced by a significant Seed Round investment on 16 August 2023 from Matrix Partners China.

With collaborations spanning both domestic state-owned enterprises and international firms, Microcyto has established itself as a pivotal player in the biotechnological manufacturing sector. The company's growth trajectory and strategic industry partnerships present a compelling opportunity for further investment.

Taxonomy: synthetic biology, biomanufacturing, biotech industry, investment funding, collaborations, active pharmaceutical ingredients, high value natural products, platform compounds, China Science Academy, Tsinghua University, Sichuan University, drug development, industrial biotechnology, multi-sector applications

Services & Products

Innovation in human nutrition and health through novel food ingredients
Bio-based animal nutrition solutions
Advanced pharmaceutical raw materials
Natural personal care ingredients
Agri-biologicals for enhanced crop production
Development of biological base materials

Target Customers

Food & Beverage Companies Agricultural and Aquaculture Industries Pharmaceutical Manufacturers Personal Care Product Companies Environmental and Sustainability Organizations

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round •••••• 1
Investor
16 Aug 2023
Seed Round •••••• 4
Investor
•••• ••••
06 Jul 2023
Angel Round •••••• 4
Investor Investor Investor
•••• ••••
30 May 2022

Microcyto微元合成 Alternatives & Competitors

View All Alternatives
Microcyto微元合成 vs
The Jambar
The Jambar United States

The Student Voice of Youngstown State University Since 1931.

Grant
40 employees
Telecom
Microcyto微元合成 vs

Interdisciplinary and at the forefront of fundamental AI research.

59 employees
Microcyto微元合成 vs
ApoGlyx
ApoGlyx Sweden

We are developing aquaporin inhibitor technology for pharmaceutical treatments of sepsis and diabete...

Series Unknown
5 employees
Biotechnology

FAQ About Microcyto微元合成

微元合成(Microcyto)是一家以合成生物技术为基础的生物制造公司,至今 已完成多家明星投资机构参与的大额融资,已与多家国企和外企建立了广泛的交流与合作。公司业务聚焦于活性原料药、高附加值天然产物和大宗平台化合物等品类。
Microcyto微元合成 was founded in 2021.
Microcyto微元合成 is headquartered in China.
Microcyto微元合成 operates in the following industries: Biotechnology, Food and Beverage, Manufacturing.
Microcyto微元合成 has approximately 7 employees.
Microcyto微元合成 has completed 3 funding rounds, raising a total of $100.00M. The latest funding stage is Seed.
Microcyto微元合成 offers: Innovation in human nutrition and health through novel food ingredients, Bio-based animal nutrition solutions, Advanced pharmaceutical raw materials, Natural personal care ingredients, Agri-biologicals for enhanced crop production, Development of biological base materials.
Top alternatives and competitors to Microcyto微元合成 include The Jambar, Pioneer Centre for AI, ApoGlyx, OpenSpecimen (Biobanking LIMS), Scholist. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Microcyto微元合成 and The Jambar are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Microcyto微元合成 and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy